CA2912025A1 - Novel formulation of cilostazol, a quinolinone-derivative used for alleviating the symptom of intermittent claudication in patients with peripheral vascular disease - Google Patents

Novel formulation of cilostazol, a quinolinone-derivative used for alleviating the symptom of intermittent claudication in patients with peripheral vascular disease Download PDF

Info

Publication number
CA2912025A1
CA2912025A1 CA2912025A CA2912025A CA2912025A1 CA 2912025 A1 CA2912025 A1 CA 2912025A1 CA 2912025 A CA2912025 A CA 2912025A CA 2912025 A CA2912025 A CA 2912025A CA 2912025 A1 CA2912025 A1 CA 2912025A1
Authority
CA
Canada
Prior art keywords
cellulose
pharmaceutical composition
combination
cilostazol
diluent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2912025A
Other languages
English (en)
French (fr)
Inventor
Fengchu Chen
Yinshan Wang
Yilun YANG
Yuying Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENOVATE BIOTECHNOLOGY CO Ltd
Original Assignee
GENOVATE BIOTECHNOLOGY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENOVATE BIOTECHNOLOGY CO Ltd filed Critical GENOVATE BIOTECHNOLOGY CO Ltd
Publication of CA2912025A1 publication Critical patent/CA2912025A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2912025A 2014-11-18 2015-11-12 Novel formulation of cilostazol, a quinolinone-derivative used for alleviating the symptom of intermittent claudication in patients with peripheral vascular disease Abandoned CA2912025A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/546,864 US20160136282A1 (en) 2014-11-18 2014-11-18 Novel formulation of cilostazol, a quinolinone-derivative used for alleviating the symptom of intermittent claudication in patients with peripheral vascular disease
US14/546864 2014-11-18

Publications (1)

Publication Number Publication Date
CA2912025A1 true CA2912025A1 (en) 2016-05-18

Family

ID=54704975

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2912025A Abandoned CA2912025A1 (en) 2014-11-18 2015-11-12 Novel formulation of cilostazol, a quinolinone-derivative used for alleviating the symptom of intermittent claudication in patients with peripheral vascular disease

Country Status (8)

Country Link
US (1) US20160136282A1 (enExample)
EP (1) EP3023094B1 (enExample)
JP (1) JP6995463B2 (enExample)
KR (1) KR20160059442A (enExample)
CN (1) CN105596304B (enExample)
AU (1) AU2015252455A1 (enExample)
CA (1) CA2912025A1 (enExample)
TW (1) TWI728960B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI845802B (zh) * 2020-04-21 2024-06-21 健亞生物科技股份有限公司 硫酸羥氯喹之晶體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4641696B2 (ja) * 1999-09-30 2011-03-02 大塚製薬株式会社 消化管下部溶解性コーティング製剤
CN100350977C (zh) * 2001-06-14 2007-11-28 大塚制药株式会社 药物组合物
JP5084089B2 (ja) * 2001-06-14 2012-11-28 大塚製薬株式会社 医薬組成物
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions
US20080206348A1 (en) * 2004-09-17 2008-08-28 Deepak Murpani Cilostazol-Containing Pharmaceutical Composition Based On Particles Of Less Than 50 Micrometers
ATE398451T1 (de) 2005-08-29 2008-07-15 Teva Pharma Festes, teilchenförmiges tadalafil mit bimodaler teilchengrössenverteilung
US20110165236A1 (en) * 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
US20080181947A1 (en) * 2006-09-26 2008-07-31 Astellas Pharma Inc. Controlled release dosage form of tacrolimus
KR20080076440A (ko) * 2007-02-16 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
PH12012500546A1 (en) * 2009-09-23 2017-04-19 Korea United Pharm Inc Slow-release cilostazol tablet having improved elution rate and minimal side effects
CN104487057A (zh) * 2012-05-11 2015-04-01 韩诺生物制药株式会社 波生坦控释口服制剂

Also Published As

Publication number Publication date
EP3023094B1 (en) 2021-07-14
KR20160059442A (ko) 2016-05-26
JP2016098230A (ja) 2016-05-30
TWI728960B (zh) 2021-06-01
CN105596304B (zh) 2020-10-16
US20160136282A1 (en) 2016-05-19
CN105596304A (zh) 2016-05-25
TW201618784A (zh) 2016-06-01
AU2015252455A1 (en) 2016-06-02
JP6995463B2 (ja) 2022-01-14
EP3023094A1 (en) 2016-05-25

Similar Documents

Publication Publication Date Title
JP4463875B2 (ja) 医薬組成物
AU2011260608B2 (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
KR100845660B1 (ko) 서방성 파라세타몰 조성물
JP2020535158A (ja) ニラパリブ処方物
NO330260B1 (no) Oral, fast sammensetning omfattende levodopa/carbidopa/entacapon, fremgangsmate for fremstilling derav, samt anvendelse av en sammensetning omfattende levodopa/carbidopa/entacapon for fremstilling av et medikament til behandling av Parkinsons sykdom.
CA2992404C (en) Pharmaceutical composition containing celecoxib and tramadol
US11382912B2 (en) Controlled-release preparation
TW202038917A (zh) 包含托法替尼或其藥學上可接受的鹽類的延長釋放配方及其製備方法
KR101923403B1 (ko) 리마프로스트 또는 리마프로스트 알파엑스를 함유한 경구용 서방성 제제 조성물
WO2022144919A1 (en) Extended release pharmaceutical compositions of riociguat
HK1208130A1 (en) Extended-release levetiracetam and method of preparation
JP2017523149A (ja) エドキサバンの医薬組成物
EP3023094B1 (en) Novel formulation of cilostazol
JP2010511023A (ja) メマンチンの製剤組成物
JP2016098230A5 (enExample)
KR101920307B1 (ko) 고정용량의 실로스타졸 서방출 및 스타틴 일반방출 미니정제를 포함하는 1일 1회 경구복용 복합 캡슐제 및 이의 제조방법
EP2277511A1 (en) Extended release pharmaceutical compositions of levetiracetam
Narla et al. Formulation and evaluation of sustained release metoprolol succinate matrix tablets by direct compression process by using Kollidon SR
KR20250164210A (ko) (4s)-24-클로로-4-에틸-73-플루오로-35-메톡시-32,5-디옥소-14-(트리플루오로메틸)-32h-6-아자-3(4,1)-피리디나-1(1)-[1,2,3]트리아졸라-2(1,2),7(1)-디벤제나헵타판-74-카르복스아미드를포함하는 제약 투여 형태
WO2014167439A1 (en) Modified release pharmaceutical compositions of topiramate or salts thereof
Patel et al. Formulation and evaluation of time delayed release tablet of carvedilol phosphate
HK40036074A (en) Controlled release formulation
KR20100003851A (ko) 가용화된 니플루믹산을 함유하는 서방성 정제

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220203

FZDE Discontinued

Effective date: 20220203